{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:15:03Z","timestamp":1771931703611,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The study bridge statistical pharmacovigilance signals to clinically actionable insights by systematically characterizing adverse event (AE) patterns associated with ublituximab and identifying previously unrecognized risks. We aim to establish a quantitative framework to inform real-world safety monitoring protocols and regulatory risk-benefit evaluations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically analyzed AE reports associated with ublituximab through a comprehensive retrospective study of FAERS and VigiAccess databases (data cutoff: December 29, 2024). Utilizing five validated disproportionality analysis methods\u2014the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), Medicines and Healthcare Products Regulatory Agency algorithm (MHRA), and Multi-Item Gamma Poisson Shrinker (MGPS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our investigation integrated 2, 245 case reports from the FAERS with 2, 037 entries in VigiAccess database. Signal detection via the ROR and PRR uncovered 52 preferred term (PT)-level signals significantly associated with ublituximab in the FAERS database, corresponding to 20 system organ class (SOCs). Notably, four SOCs - encompassing cardiovascular disorders, vascular pathologies, urinary system conditions, and social environment factors - were identified with disproportionality signals but currently lack documentation in approved prescribing information. We identified 8 frequently reported PTs (hypoaesthesia, fall, gait disturbance, paraesthesia, balance disorder, alopecia, tremor, and somnolence) within the top 50 AEs showed disproportionality signals but remain unlisted in the current drug lable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study has identified confirmed positive signals associated with ublituximab and revealed potential signals of interest. These findings highlight the need for further regulatory review to assess whether the identified signals justify updates to drug labeling and therapeutic guidelines. Future investigations should build upon the AE signals established in this research, with further investigations warranted to elucidate both the clinical incidence rates of these AEs and their definitive causal relationships with ublituximab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1738185","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:22:22Z","timestamp":1770960142000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A real-world study of ublituximab based on the WHO-VigiAccess and U.S. food and drug administration\u2019s adverse event reporting system databases"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiagnang","family":"Cao","sequence":"first","affiliation":[{"name":"Institute of Clinical Pharmacy Research, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China","place":["Hengyang, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinguo","family":"Shen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine","place":["Linyi, Shangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zou","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacy Research, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China","place":["Hengyang, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/wco.0000000000000622","article-title":"Multiple sclerosis: clinical aspects","volume":"31","author":"Oh","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020266","article-title":"Advances in multiple sclerosis","volume":"13","author":"Rivera","year":"2025","journal-title":"Biomedicines"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.S388410","article-title":"Evaluating the therapeutic potential of ublituximab in the treatment of MS: design, development and place in therapy","volume":"18","author":"Martin","year":"2024","journal-title":"Drug Des Dev Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0035-2","article-title":"Progressive multiple sclerosis: from pathophysiology to therapeutic strategies","volume":"18","author":"Faissner","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01854-z","article-title":"Ublituximab: first approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12007-3","article-title":"Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment","volume":"271","author":"Delgado","year":"2024","journal-title":"J Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520918375","article-title":"A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis","volume":"27","author":"Fox","year":"2021","journal-title":"Mult Scler"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104733","article-title":"Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis","volume":"75","author":"Boldrini","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1473284","article-title":"Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis","volume":"15","author":"Alvarez","year":"2024","journal-title":"Front Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/14740338.2024.2416917","article-title":"Safety study on adverse events of zanubrutinib based on WHO-VigiAccess and FAERS databases","volume":"25","author":"He","year":"2026","journal-title":"Expert Opin Drug Saf"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1169327","article-title":"Characteristic analysis of adverse reactions of five anti-TNF\u03b1 agents: a descriptive analysis from WHO-VigiAccess","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s43441-022-00393-1","article-title":"MedDRA labeling groupings to improve safety communication in product labels","volume":"57","author":"Gro\u00dfe-Michaelis","year":"2023","journal-title":"Ther Innovation Regul Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2268842","article-title":"Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis","volume":"23","author":"Jakimovski","year":"2023","journal-title":"Expert Rev Neurother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.3390\/v15112220","article-title":"Prolonged SARS-coV-2 infection in patients receiving anti-CD20 monoclonal antibodies: A diagnostic challenged by negative nasopharyngeal RT-PCR and successful treatment with COVID-19 high-titer convalescent plasma","volume":"15","author":"Da Silva","year":"2023","journal-title":"Viruses"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e200264","DOI":"10.1212\/NXI.0000000000200264","article-title":"Neonatal B-cell levels and infant health in newborns potentially exposed to anti-CD20 monoclonal antibodies during pregnancy or lactation","volume":"11","author":"Schwake","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e200349","DOI":"10.1212\/NXI.0000000000200349","article-title":"Pregnancy and infant outcomes in women with multiple sclerosis treated with ocrelizumab","volume":"12","author":"Vukusic","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200021","article-title":"Updated results of the COVID-19 in MS global data sharing initiative: anti-CD20 and other risk factors associated with COVID-19 severity","volume":"9","author":"Simpson-Yap","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"New Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14534","article-title":"A phase 1\/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab","volume":"177","author":"Sawas","year":"2017","journal-title":"Br J Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00446-x","article-title":"Ublituximab: a new anti-CD20 agent for multiple sclerosis","volume":"21","author":"Oh","year":"2022","journal-title":"Lancet Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108180","article-title":"Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease","volume":"238","author":"Chen","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1042\/cs20230513","article-title":"The complement system in neurodegenerative diseases","volume":"138","author":"Nimmo","year":"2024","journal-title":"Clin Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.77503","article-title":"Soluble MAC is primarily released from MAC-resistant bacteria that potently convert complement component C5","volume":"11","author":"Doorduijn","year":"2022","journal-title":"eLife"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxac090","article-title":"Cytokine production by human B cells: role in health and autoimmune disease","volume":"210","author":"de Gruijter","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.83561","article-title":"B cell receptor-induced IL-10 production from neonatal mouse CD19(+)CD43(-) cells depends on STAT5-mediated IL-6 secretion","volume":"12","author":"Sakai","year":"2023","journal-title":"ELIFE"},{"key":"B28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41467-023-44584-2","article-title":"Genomic and panproteomic analysis of the development of infant immune responses to antigenically-diverse pneumococci","volume":"15","author":"Croucher","year":"2024","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c00354","article-title":"Exploring how antibody format drives clearance from the brain","volume":"21","author":"Schwinghamer","year":"2024","journal-title":"Mol Pharmaceutics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac019","article-title":"Intrinsic blood-brain barrier dysfunction contributes to multiple sclerosis pathogenesis","volume":"145","author":"Nishihara","year":"2022","journal-title":"Brain: A J Neurol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00711","article-title":"PECAM-1 stabilizes blood-brain barrier integrity and favors paracellular T-cell diapedesis across the blood-brain barrier during neuroinflammation","volume":"10","author":"Wimmer","year":"2019","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225474","article-title":"Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma","volume":"114","author":"Li","year":"2009","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.841548","article-title":"Clemastine induces an impairment in developmental myelination","volume":"10","author":"Palma","year":"2022","journal-title":"Front Cell Dev Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1738185\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:28:07Z","timestamp":1771928887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1738185\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2026.1738185"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1738185","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"article-number":"1738185"}}